Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Rtw Biotech (RTW)

Price $1.48 on 22-11-2024 at 17:30:01
Change $0.00 0%
Buy $1.47
Sell $1.46
Buy / Sell RTW Shares
Last Trade: Buy 50.00 at $1.48
Day's Volume: 205,649
Last Close: $1.48
Open: $1.47
ISIN: GG00BKTRRM22
Day's Range $1.46 - $1.48
52wk Range: $1.15 - $1.73
Market Capitalisation: $497m
VWAP: $1.472654
Shares in Issue: 336m

Recent Trades History Rtw Biotech (RTW)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 50 $1.48 Suspected BUY Trade
16:35:26 - 22-Nov-24
Sell* 2,152 $1.47 Automatic Execution
16:18:19 - 22-Nov-24
Sell* 2,713 $1.47 Automatic Execution
16:18:09 - 22-Nov-24
Sell* 7,440 $1.47 Automatic Execution
16:18:09 - 22-Nov-24
Sell* 227 $1.47 Automatic Execution
16:18:02 - 22-Nov-24
Sell* 11,139 $1.47 Automatic Execution
16:17:59 - 22-Nov-24
Sell* 16,733 $1.47 Automatic Execution
16:17:49 - 22-Nov-24
Sell* 1,000 $1.463 Ordinary
15:14:01 - 22-Nov-24
Sell* 1,000 $1.463 Ordinary
15:13:31 - 22-Nov-24
Sell* 1,000 $1.463 Ordinary
15:12:30 - 22-Nov-24

Share Price History for Rtw Biotech

Time period:
to
Date Open High Low Close Volume

Share News for Rtw Biotech

IN BRIEF: RTW Biotech notes drug approval in China for investee Corxel

15th Nov 2024 10:02

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Notes Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd, formerly Ji Xing Pharmaceuticals Ltd, has had its new drug application for Aficamten accepted by China's National Medical Products Administration. Aficamten is a drug treatment for obstructive hypertrophic cardiomyopathy, a genetic heart condition diagnosed in around 130,000 to 330,000 patients in China, in which the heart muscle becomes abnormally thick and limits the heart's pumping function. The drug has also received breakthrough therapy designation from the US Food & Drug Administration. Corxel was founded and launched by RTW Investments in 2019. Read More

IN BRIEF: RTW Biotech invests in inflammation treatment firm Evommune

4th Nov 2024 06:50

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes an investment in new portfolio company Evommune Inc, a biotechnology company developing therapies for chronic inflammatory disease, as part of a Series C funding round. The company received a legacy position in Evommune earlier this year after its acquisition of Arix Bioscience and its assets. Read More

RTW Biotech Opportunities announces launch of Kailera Therapeutics

3rd Oct 2024 12:59

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced the launch of Kailera Therapeutics, a new investee company, with a series A financing round. Read More

IN BRIEF: RTW Biotech invests in cancer treatment firm Aktis Oncology

2nd Oct 2024 11:05

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in life sciences sector - Invests in Boston, Massachusetts-based Aktis Oncology Inc, a clinical-stage developer of novel targeted alpha radiopharmaceuticals to treat a range of solid tumours. Alongside other investment vehicles owned by RTW Investments, RTW Biotech co-led Aktis's series B funding round, raising USD175 million. Read More

RTW Biotech notes BioAge Labs' USD198 million initial public offering

27th Sep 2024 12:19

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering. Read More

FTSE 100 Latest
Value8,262.08
Change112.81

Login to your account

Forgot Password?

Not Registered